You just read:

Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy

News provided by

Actinium Pharmaceuticals, Inc.

Feb 21, 2019, 08:00 ET